Novartis AG
NVSEF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $241 | $234 | $216 | $191 |
| - Cash | $10 | $7 | $7 | $11 |
| + Debt | $32 | $33 | $31 | $31 |
| Enterprise Value | $263 | $260 | $241 | $211 |
| Revenue | $14 | $15 | $14 | $14 |
| % Growth | -3.2% | 8.9% | 0.5% | – |
| Gross Profit | $11 | $12 | $10 | $10 |
| % Margin | 75.4% | 77.6% | 76.3% | 75.5% |
| EBITDA | $6 | $6 | $6 | $5 |
| % Margin | 40.7% | 41% | 42.8% | 38.3% |
| Net Income | $4 | $4 | $4 | $3 |
| % Margin | 27.4% | 27.2% | 26.9% | 20.8% |
| EPS Diluted | 2 | 2.06 | 1.82 | 1.41 |
| % Growth | -2.9% | 13.2% | 29.1% | – |
| Operating Cash Flow | $7 | $7 | $4 | $4 |
| Capital Expenditures | -$1 | -$1 | -$0 | -$1 |
| Free Cash Flow | $6 | $6 | $3 | $3 |